Stomach Cancer
120
22
26
52
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
16 trials with published results (13%)
Research Maturity
52 completed trials (43% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
10 terminated out of 120 trials
83.9%
-2.6% vs benchmark
8%
9 trials in Phase 3/4
31%
16 of 52 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 52 completed trials
Clinical Trials (120)
Large Language Models Assist in Tumor MDT
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
Cancer Loyalty Card Study 2 (CLOCS-2)
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
The PLATON Network
Multigene Germline Panel Testing in Gastric Cancer Patients in Portugal
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Evaluation of the NEOmom® Gastric Video Capsule for Gastric Cancer Screening
Target-specific immunoPET Imaging of Digestive System Carcinoma
Robotic Gastrectomy With 5th Arm
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
Avutometinib and Defactinib in Diffuse Gastric Cancer
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)